NDA 206255 · Galderma Labs Lp
Soolantra
Ivermectin · Topical · Antiparasitic; Pediculicide
Last checked: Nov 19, 2026Latest source record: Oct 14, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Dec 19, 2014
Approved uses
1
Original approval plus efficacy supplements
Registered trials
221
83 Phase 3, 9 recruiting
FAERS reports
4,016
2,204 serious, 337 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 24, 2024.
SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. SOOLANTRA cream is indicated for the treatment of inflammatory lesions of rosacea. ( 1 )
Mechanism: The mechanism of action of SOOLANTRA cream in treating rosacea lesions is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- SOOLANTRA · IVERMECTIN 1% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Ivermectin" as an intervention, any sponsor and status, largest first.
- Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical DiseasesPivotal-lookingRecruiting
Kirby InstituteGovernment (non-federal)
NCT07145736 · 52,000 participants (planned) · Start Aug 4, 2025 · Primary completion Mar 31, 2029
Drug: Moxidectin; Ivermectin · For: Onchocerciasis; Ascaris Lumbricoides Infection; Trichuris Trichiura; Infection and 2 more
Sites: Andulo, Angola
- Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)Pivotal-lookingCompleted
Barcelona Institute for Global HealthAcademic, hospital or other
NCT04966702 · 48,145 participants · Start Mar 17, 2022 · Primary completion Apr 15, 2024
Drug: Albendazole Pill; Ivermectin Pill and 1 more · For: Malaria
Sites: Kwale, Kenya; Mopeia, Mozambique
- Adjunctive Ivermectin Mass Drug Administration for Malaria ControlPivotal-lookingStatus unknown
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT04844905 · 24,000 participants (planned) · Start May 3, 2021 · Primary completion Mar 2023
Drug: Ivermectin; Placebo and 1 more · For: Malaria,Falciparum; Neglected Tropical Diseases; Strongyloidiasis and 4 more
Sites: Bissau, Guinea-Bissau
- Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic FilariasisPivotal-lookingCompleted
Washington University School of MedicineAcademic, hospital or other
NCT02899936 · 23,789 participants · Start Jul 2016 · Primary completion Apr 27, 2017
Drug: 3 drug dose - IDA; 2 drug dose - DA · For: Lymphatic Filariasis
Sites: Port-au-Prince, Haiti; Puducherry, India; Jakarta, Indonesia · 4 sites in all
- Safety of Co-administration of IDA and Azithromycin for NTDs ( ComboNTDs )Pivotal-lookingCompleted
Lihir Medical CentreAcademic, hospital or other
NCT03676140 · 20,000 participants · Start Oct 1, 2018 · Primary completion Dec 15, 2018
Drug: Albendazole on Day 1; Ivermectin on Day 1 and 3 more · For: Trachoma; Yaws; Lymphatic Filariases and 2 more
Sites: Namatanai, Papua New Guinea
- Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and EffectivenessPivotal-lookingRecruiting
Insud PharmaIndustry
NCT06282315 · 20,000 participants (planned) · Start Sep 1, 2025 · Primary completion Apr 2026
Drug: Pre-screening Phase; Screenig Phase and 6 more · For: Soil-Transmitted Helminths
Sites: Accra, Ghana; Nairobi, Kenya
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Insecticide Resistance Management in Burkina Faso and Côte D'IvoirePivotal-lookingCompleted
Institut de Recherche pour le DeveloppementGovernment (non-federal)
NCT03074435 · 15,776 participants · Start Jul 2016 · Primary completion Aug 2018
Drug: Ivermectin · For: Malaria
Sites: Bobo-Dioulasso, Burkina Faso; Bouaké, Côte d’Ivoire
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective465
- off label use420
- product use in unapproved indication290
- erythema224
- headache201
- pruritus184
- rash163
- rosacea161
- fatigue154
- nausea140
- condition aggravated139
- diarrhoea128
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 3 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 3 |
| 2011 | 11 |
| 2012 | 6 |
| 2013 | 31 |
| 2014 | 46 |
| 2015 | 186 |
| 2016 | 186 |
| 2017 | 163 |
| 2018 | 185 |
| 2019 | 244 |
| 2020 | 281 |
| 2021 | 506 |
| 2022 | 403 |
| 2023 | 347 |
| 2024 | 358 |
| 2025 | 578 |
| 2026 | 451 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Soolantra (IVermectin)
2024 spending
$1.4M
Beneficiaries
903
1,911 claims
Per beneficiary
$1,538
$15.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,533,739 |
| 2021 | $7,452,312 |
| 2022 | $3,162,224 |
| 2023 | $1,955,560 |
| 2024 | $1,388,735 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.
Tang M, Hu X, Wang Y, et al. · Pharmacol Res 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Failure of scabies treatment: a systematic review and meta-analysis.
Mbuagbaw L, Sadeghirad B, Morgan RL, et al. · Br J Dermatol 2024 · Meta-Analysis, Systematic Review
- Oral ivermectin versus 5% permethrin cream to treat children and adults with classic scabies: multicentre, assessor blinded, cluster randomised clinical trial.
Boralevi F, Simon G, Bernigaud C, et al. · BMJ 2026 · Multicenter Study, Randomized Controlled Trial
- Ivermectin to Control Malaria - A Cluster-Randomized Trial.
Chaccour C, Maia M, Kariuki M, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Multicenter Study
- Efficacy of Widely Used Topical Drugs for Rosacea: A Systematic Review and Meta-Analysis.
Gao X, Xiang W · Actas Dermosifiliogr 2025 · Systematic Review, Meta-Analysis
- Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Galderma Labs Lp
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.